Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis

This study aimed to investigate the long-term outcomes of sulfonylurea (SU) use in patients with T2DM and compensated liver cirrhosis. From January 1, 2000, to December 31, 2012, we selected the data of 3781 propensity-score-matched SU users and nonusers from Taiwan's National Health Insurance...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-12, Vol.15 (12), p.e0243783
Main Authors: Yen, Fu-Shun, Lai, Jung-Nien, Wei, James Cheng-Chung, Chiu, Lu-Ting, Hwu, Chii-Min, Hou, Ming-Chih, Hsu, Chih-Cheng
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Ascites
Biology and Life Sciences
Blood sugar
Body mass index
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - etiology
Care and treatment
Chronic obstructive pulmonary disease
Cirrhosis
Comorbidity
Confidence intervals
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - mortality
Dose-Response Relationship, Drug
Esophagus
Female
Gastrointestinal surgery
Glucose
Health aspects
Health hazards
Health insurance
Health risks
Heart failure
Hepatitis
Hospitals
Humans
Hypoglycemia
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Hypoglycemic sulfonylureas
Incidence
Insulin resistance
Liver
Liver cirrhosis
Liver Cirrhosis - complications
Liver Cirrhosis - mortality
Longitudinal Studies
Male
Medicine
Medicine and Health Sciences
Middle Aged
Mortality
Obesity
Overweight
Patients
Physiological aspects
Population studies
Propensity Score
Proportional Hazards Models
Risk Factors
Standard error
Statistical models
Sulfonylurea
Sulfonylurea compounds
Sulfonylurea Compounds - adverse effects
Sulfonylurea Compounds - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to investigate the long-term outcomes of sulfonylurea (SU) use in patients with T2DM and compensated liver cirrhosis. From January 1, 2000, to December 31, 2012, we selected the data of 3781 propensity-score-matched SU users and nonusers from Taiwan's National Health Insurance Research Database. The mean follow-up time for this study was 5.74 years. Cox proportional hazards models with robust sandwich standard error estimates were used to compare the risks of main outcomes between SU users and nonusers. The incidence of mortality during follow-up was 3.24 and 4.09 per 100 person-years for SU users and nonusers, respectively. The adjusted hazard ratios and 95% confidence intervals for all-cause mortality, major cardiovascular events, and decompensated cirrhosis in SU users relative to SU nonusers were 0.79 (0.71-0.88), 0.69 (0.61-0.80), and 0.82 (0.66-1.03), respectively. The SU-associated lower risks of death and cardiovascular events seemed to have a dose-response trend. This population-based cohort study demonstrated that SU use was associated with lower risks of death and major cardiovascular events compared with SU non-use in patients with T2DM and compensated liver cirrhosis. SUs may be useful for glycemic management for patients with liver cirrhosis.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0243783